抗视网膜脉络膜新生血管性疾病治疗药物靶点的研究进展

doi:10.16352/j.issn.1001-6325.2022.02.011

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (2): 325-329.doi: 10.16352/j.issn.1001-6325.2022.02.011

抗视网膜脉络膜新生血管性疾病治疗药物靶点的研究进展

刘辰¹, 方思尹¹, 顾操¹, 吴晋晖^2*

1.海军军医大学第一附属医院眼科, 上海 200433;
2.海军军医大学第三附属医院眼科,上海 200438

收稿日期:2021-03-29 修回日期:2021-08-13 发布日期:2022-01-24
通讯作者: ^* wjh2042@aliyun.com
基金资助:
上海市浦江人才项目(17PJD041);海军军医大学,未来战争医学防护技术研发专项(19WLMS-03);上海市中医药管理局(ZHYY-ZXYJHZX-202024)

Research progress on drug targets for anti-retinal and choroidal neovascular diseases

LIU Chen¹, FANG Si-yin¹, GU Cao¹, WU Jin-hui^2*

1. Department of Ophthalmology, the First Affiliated Hospital, Navy Military Medical University, Shanghai 200433;
2. Department of Ophthalmology, the Third Affiliated Hospital, Navy Military Medical University,Shanghai 200438, China

Received:2021-03-29 Revised:2021-08-13 Published:2022-01-24
Contact: ^* wjh2042@aliyun.com

摘要/Abstract

摘要： 新生血管性年龄相关性黄斑变性(nAMD)、糖尿病视网膜病变(DR)等眼底病继发形成新生血管,是致盲的重要原因之一。抗血管内皮生长因子(VEGF)治疗是当前主流疗法。但仍存在部分患者对其疗效欠佳等局限,临床仍需要开发新的药物靶点。

关键词: 视网膜, 脉络膜, 新生血管, 药物靶点

Abstract: The appearance of new blood vessels in the neovascular age-related macular degeneration (nAMD), diabetic retinopathy (DR),and other ocular diseases is one of the important reasons for blindness. Anti-vascular endothelial growth factor (VEGF) drugs are the current mainstream. However, some patients have poor efficacy and other adverse reactions. There is still a need to develop new drugs.

Key words: retina, choroid, revascularization, drug targets

中图分类号:

R774.1

刘辰, 方思尹, 顾操, 吴晋晖. 抗视网膜脉络膜新生血管性疾病治疗药物靶点的研究进展[J]. 基础医学与临床, 2022, 42(2): 325-329.

LIU Chen, FANG Si-yin, GU Cao, WU Jin-hui. Research progress on drug targets for anti-retinal and choroidal neovascular diseases[J]. Basic & Clinical Medicine, 2022, 42(2): 325-329.

参考文献

[1]Xu K, Li B, Zhang S, et al. DCZ3301, an aryl-guanidino agent, inhibits ocular neovascularization via PI3K/AKT and ERK1/2 signaling pathways[J]. Exp Eye Res, 2020, 201:108267.doi: 10.1016/j.exer.2020.108267.
[2]Zheng Y, Liu Y, Wang L, et al. MicroRNA-126 suppresses the proliferation and migration of endothelial cells in experimental diabetic retinopathy by targeting polo-like kinase 4[J]. Int J Mol Med, 2021, 47:151-160.
[3]Chakravarthy U, Havilio M, Syntosi A, et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD[J]. Eye (Lond), 2021. doi: 10.1038/s41433-020-01354-4.
[4]Yin X, Lin X, Ren X, et al. Novel multi-targeted inhibitors suppress ocular neovascularization by regulating uni-que gene sets[J]. Pharmacol Res, 2019, 146:104277. doi: 10.1016/j.phrs.2019.104277.
[5]Angermann R, Rauchegger T, Nowosielski Y, et al. Systemic counterregulatory response of angiopoietin-2 after aflibercept therapy for nAMD: a potential escape mechanism[J]. Acta Ophthalmol, 2020. doi: 10.1111/aos.14691.
[6]Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema[J]. Ophthalmology, 2019, 126:1155-1170.
[7]Ding K, Eaton L, Bowley D, et al. Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degeneration[J]. MAbs, 2017, 9:269-284.
[8]Liu Y, Feng M, Cai J, et al. Repurposing bortezomib for choroidal neovascularization treatment via antagonizing VEGF-A and PDGF-D mediated signaling[J]. Exp Eye Res, 2021, 204:108446. doi: 10.1016/j.exer.2021.108446.
[9]Li Y, Hu D, Lv P, et al. Expression of platelet-derived growth factor-C in aqueous humor of patients with neovascular glaucoma and its correlation with vascular endothelial growth factor[J]. Eur J Ophthalmol, 2020, 30:500-505.
[10]Miwa Y, Hoshino Y, Shoda C, et al. Pharmacological HIF inhibition prevents retinal neovascularization with improved visual function in a murine oxygen-induced retinopathy model[J]. Neurochem Int, 2019, 128:21-31.
[11]Zeng M, Shen J, Liu Y, et al. The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization[J]. J Mol Med (Berl), 2017, 95:417-429.
[12]Sheibani N, Wang S, Darjatmoko SR, et al. Novel anti-angiogenic PEDF-Derived small peptides mitigate, choroidal neovascularization[J]. Exp Eye Res, 2019, 188:107798. doi: 10.1016/j.exer.2019.107798.
[13]Kim HW, Roh KH, Kim SW, et al. Type I pig collagen enhances the efficacy of PEDF 34-mer peptide in a mouse model of laser-induced choroidal neovascularization[J]. Graefes Arch Clin Exp Ophthalmol, 2019, 257:1709-1717.
[14]Zhang X, Wu J, Wu C, et al. Comparison of aqueous humor levels of PlGF and VEGF in proliferative diabetic retinopathy before and after intravitreal conbercept injection[J]. Diabetes Res Clin Pract, 2020, 162:108083. doi: 10.1016/j.diabres.2020.108083.
[15] Lazzara F, Fidilio A, Platania CBM, et al. Aflibercept regulates retinal inflammation elicited by high glucose via the PlGF/ERK pathway[J]. Biochem Pharmacol, 2019, 168: 341-351.
[16] Dong Z, Santeford A, Ban N, et al. FGF2-induced STAT3 activation regulates pathologic neovascularization[J]. Exp Eye Res,2019, 187:107775. doi: 10.1016/j.exer.2019.107775.
[17]Hosaka K, Yang Y, Nakamura M, et al. Dual roles of endothelial FGF-2-FGFR1-PDGF-BB and perivascular FGF-2-FGFR2-PDGFRβ signaling pathways in tumor vascular remodeling[J]. Cell Discov, 2018, 4:3. doi: 10.1038/s41421-017-0002-1.
[18]Lee SHS, Chang H, Kim HJ, et al. Effects of Stuffer DNA on the suppression of choroidal neovascularization by a rAAV expressing a mTOR-inhibiting shRNA[J]. Mol Ther Methods Clin Dev, 2019, 14:171-179.
[19]Wang C, Ma J, Xu M, et al. mTORC1 signaling pathway regulates macrophages in choroidal neovascularization[J]. Mol Immunol,2020, 121:72-80.
[20]Terao R, Honjo M, Totsuka K,et al. The role of sphingosine 1-phosphate receptors on retinal pigment epithelial cells barrier function and angiogenic effects[J]. Prostaglandins Other Lipid Mediat, 2019, 145:106365. doi: 10.1016/j.prostaglandins.2019.106365.
[21]Arnst KE, Wang Y, Hwang DJ,et al. A potent, metabolically stable tubulin inhibitor targets the colchicine binding site and overcomes taxane resistance[J]. Cancer Res, 2018, 78:265-277.

抗视网膜脉络膜新生血管性疾病治疗药物靶点的研究进展

Research progress on drug targets for anti-retinal and choroidal neovascular diseases

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张佳, 王艳丽, 宋晓丛, 王淑珍. 张家口市高血压视网膜病变患者情况调查及危险因素分析[J]. 基础医学与临床, 2024, 44(6): 853-857.
[2]	魏丹丹, 宋宇涵, 王淇, 宿树兰, 朱悦, 段金廒. 年龄相关性黄斑变性的研究进展[J]. 基础医学与临床, 2024, 44(4): 553-557.
[3]	肖星宇, 戴荣平. 中心性浆液性脉络膜视网膜病变眼部特征的研究进展[J]. 基础医学与临床, 2024, 44(1): 131-135.
[4]	周悦, 林静娜. miR-199-3p通过靶向VegfA抑制大鼠糖尿病视网膜病变[J]. 基础医学与临床, 2023, 43(7): 1084-1089.
[5]	张梦瑶, 牛姝, 蔡静, 赵志刚, 周艳. miR-140-5p靶向HMGB1/IκB-α轴对糖尿病大鼠视网膜病变的影响[J]. 基础医学与临床, 2023, 43(4): 615-620.
[6]	张艺馨, 蔡善君, 李智立, 于伟泓, 张华. IgG N-糖基化修饰在糖尿病视网膜病变中作用的研究进展[J]. 基础医学与临床, 2023, 43(3): 509-513.
[7]	王卉, 苏宪, 张赢赢, 褚战亚, 孙朝晖, 张金玲, 张倩倩. 异鼠李素减轻糖尿病视网膜病变大鼠视网膜细胞凋亡[J]. 基础医学与临床, 2023, 43(2): 265-270.
[8]	方思尹, 刘辰, 吴晋晖. 微管抑制剂在血管新生性疾病中的作用机制研究进展[J]. 基础医学与临床, 2023, 43(2): 327-331.
[9]	韩亮, 卓彦伶. 哥伦比亚大学玻璃体视网膜专科医师培训启示[J]. 基础医学与临床, 2022, 42(7): 1152-1155.
[10]	游慧, 康海军, 陈方, 李恒. 高血压视网膜病变患者外周血单个核细胞Notch1水平及其与血管内皮功能的相关性[J]. 基础医学与临床, 2022, 42(10): 1528-1532.
[11]	秦建民, 张来香, 魏振英. miR-193a-3p抑制高糖诱导人视网膜血管内皮细胞凋亡[J]. 基础医学与临床, 2021, 41(7): 995-1000.
[12]	周丽萍, 毛晓春, 李琴. miR-1908抑制高糖诱导的人视网膜血管内皮细胞系HRECs凋亡[J]. 基础医学与临床, 2020, 40(8): 1090-1095.
[13]	谢芬高宋庆磊张希洲. TNF-α在视网膜神经变性性疾病中的作用[J]. 基础医学与临床, 2015, 35(2): 262-265.
[14]	申乐陈保生薛红. 重组表达人载脂蛋白（a）羧基末端kringle结构域抑制新生血管[J]. 基础医学与临床, 2013, 33(6): 655-660.
[15]	苏吉儿丁静文韩松罗宏李俊发. Müller细胞反应性胶质化在急性高眼压致大鼠视网膜损伤中作用[J]. 基础医学与临床, 2013, 33(2): 133-138.